Revista de Vertebrados de la Estación Biológica de Doñana

Dimorfismo sexual en Microtus cabrerae en base a los caracteres de su pelvis.Notas sobre la distribución y ecología de Microtus cabreae, Thomas, 1906.Alimentación de la culebra bastarda (Malpolon monspessulanus, Ophidia, Colubridae) en el S. O. de España.Selectividad en la predación de la lechuza común (Tyto alba) sobre Rano ridibunda.Variations in the food habits of the european Eagle Owl. (Bubo bubo)Contaminación en huevos de aves silvestres de lSuroeste de España por residuos organoclorados (Insecticidas y bifenilos policlorados)Sobre el status taxonómico del águila imperial ibéricaEstudio filogenético y comparativo de Microtus cabrerae y Microtus brecciensisDescripción de una nueva especie de liebre (Lepus castroviejoi), endémica de la Cordillera CantábricaPeer reviewe

Revista de Vertebrados de la Estación Biológica de Doñana

Descripción de una nueva subespecie de lagarto ágil (Lacerta agilis garzoni) de los PirineosDiet of the Montagu's Harrier (Circus pygargus) in southwestern Spain SpainObservaciones ornitológicas en la Guayana francesaDaily feeding rhythm of ducks on the marismas of the Guadalquivir and their responses to birds of preyA note on the emetic technique for obtaining food samples from passerine birds.Distribución de contaminantes organoclorados en tejidos de garza imperial (Ardea purpurea) y pato cuchara (Anas clypeata) de la Reserva Biológica de Doñana.Etograma cuantificado del gamo (Dama dama) en libertad.Peer reviewe

Revista de Vertebrados de la Estación Biológica de Doñana

The structure of a mediterranean lizard communityDiet of the eagle owl (Bubo bubo) in mediterranean SpainTamaño de la puesta y mortalidad entre los pollos del Aguila Real ibérica (Aquila chrysaetos homeyeriDistribución y frecuencia de la cópula del buitre leonado (Gyps fulvus) en el Sur de EspañaRégimen alimenticio del calamón (Porphyrio porphyrio) en las Marismas del GuadalquivilVisible migration over the Colo Doñana, Spring 1973Diet of the Red Fox (Vulpes vulpes) in the western Sierra Morena (South Spain).Microestructura del esmalte en los incisivos de Roedores. l. Variaciones con la edadDistribution and habitat of the Barbary macaque (Macaca sylvana) in North MoroccoNotas sobre distribución de los peces fluviales en el Suroeste de España.Nuevas localidades de Valencia hispanica (Pisces:Ciprinodontidae) en el Suroeste de España.Hallazgo de Natrix mauro albinaNidificación del Phoenicopterus ruber en las Marismas del Bajo GuadalquivirNido de Aythya ferina parasitado por Fulica atraNuevos datos sobre la distribución de algunos micromamífesl ibéricos (Microtus arvalís ,M. cabrerae, M. agrestís y Sorex minutus).Neomys anomalus: Nueva localidad en el Suroeste de EspañaPeer reviewe

Revista de Vertebrados de la Estación Biológica de Doñana

Materiales para una «Herpetofauna Balearica 5. Las salamanquesas y tortugas del archipiélago de CabreraEcología de una población insular mediterránea del Eslizón ibérico, Chalcides bedriagai (Sauria Scincidae).Ecología alimenticia del águila imperial ibérica (Aquila adalberti) en el Coto Doñana durante la crianza de los pollosDatos sobre la dieta invernal del colirrojo tizón (Phoenicurus ochruros) en encinares de Andalucía occidentalSobre infecciones estafilocócicas en el Aguila imperial ibérica (Aquila adalberti Brehm)Breves notas sobre el Sapo partero ibérico (Alytes cisternasii Boscá)Sobre la presencia de Hyla arborea en la provincia de BadajozAlgunas presas de Elaphe scalaris.Observaciones de Tarentola maurítanica en nido de Hirundo dauricaObservación de una culebra viperina Natrix maura en agua marinaPrimera cita de la CollaIba yebélica (Oenanthe leucopyga) en la Península ibéricaObservaciones de Phoenicopterus ruber en la Ría de Vigo (PontevedraDatos sobre el Myotis emarginatus en la Península ibérica.Peer reviewe

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Food of the common genet (Genetta genetta) in northern Africa

Peer reviewe

Evolution over Time of Ventilatory Management and Outcome of Patients with Neurologic Disease∗

OBJECTIVES: To describe the changes in ventilator management over time in patients with neurologic disease at ICU admission and to estimate factors associated with 28-day hospital mortality. DESIGN: Secondary analysis of three prospective, observational, multicenter studies. SETTING: Cohort studies conducted in 2004, 2010, and 2016. PATIENTS: Adult patients who received mechanical ventilation for more than 12 hours. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among the 20,929 patients enrolled, we included 4,152 (20%) mechanically ventilated patients due to different neurologic diseases. Hemorrhagic stroke and brain trauma were the most common pathologies associated with the need for mechanical ventilation. Although volume-cycled ventilation remained the preferred ventilation mode, there was a significant (p < 0.001) increment in the use of pressure support ventilation. The proportion of patients receiving a protective lung ventilation strategy was increased over time: 47% in 2004, 63% in 2010, and 65% in 2016 (p < 0.001), as well as the duration of protective ventilation strategies: 406 days per 1,000 mechanical ventilation days in 2004, 523 days per 1,000 mechanical ventilation days in 2010, and 585 days per 1,000 mechanical ventilation days in 2016 (p < 0.001). There were no differences in the length of stay in the ICU, mortality in the ICU, and mortality in hospital from 2004 to 2016. Independent risk factors for 28-day mortality were age greater than 75 years, Simplified Acute Physiology Score II greater than 50, the occurrence of organ dysfunction within first 48 hours after brain injury, and specific neurologic diseases such as hemorrhagic stroke, ischemic stroke, and brain trauma. CONCLUSIONS: More lung-protective ventilatory strategies have been implemented over years in neurologic patients with no effect on pulmonary complications or on survival. We found several prognostic factors on mortality such as advanced age, the severity of the disease, organ dysfunctions, and the etiology of neurologic disease